Grifols (GIFLF) Capital Leases (2015 - 2016)
Grifols' (GIFLF) quarterly Capital Leases came in at $6.9 million in Q1 2016, up 7.56% quarter-over-quarter from $6.4 million in Q4 2015.
Analysis
Grifols (GIFLF) Capital Leases (2015 - 2016) Analysis & Trends
Grifols (GIFLF) has reported Capital Leases for 2 consecutive years, with $6.9 million the latest figure, recorded in Q1 2016.
- For the quarter ending Q1 2016, Capital Leases changed N/A year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2016 stood at $6.9 million (changed N/A YoY), and the FY2015 full-year result was $6.4 million, changed N/A from the prior year.
- Capital Leases grew to $6.9 million in Q1 2016 per GIFLF's latest filing, from $6.4 million in the prior quarter.
- Across five years, Capital Leases topped out at $6.9 million in Q1 2016 and bottomed at $6.4 million in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |